Successful rechallenge with reduced dose of erlotinib in a patient with lung adenocarcinoma who developed erlotinib-associated leukocytoclastic vasculitis: A case report
- 16 March 2012
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 3 (6), 1280-1282
- https://doi.org/10.3892/ol.2012.647
Abstract
The oral tyrosine kinase inhibitors of epidermal growth factor, erlotinib and gefitinib, are active in the treatment of non-small cell lung cancer (NSCLC). However, a number of skin manifestations have been found in patients receiving erlotinib therapy. Leukocytoclastic vasculitis is a rare side-effect of erlotinib therapy. However, whether or not erlotinib treatment should be continued when disseminated ulceration of leukocytoclastic vasculitis is encountered remains to be determined. In this study, we report a patient with NSCLC who remains responsive to erlotinib treatment following successful rechallenge with a reduced dose of erlonitib after presenting with severe degree of leukoclastic vasculitis.Keywords
This publication has 6 references indexed in Scilit:
- The histological assessment of cutaneous vasculitisHistopathology, 2009
- Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II StudyJournal of Thoracic Oncology, 2008
- Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinibAnnals Of Oncology, 2007
- Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitorsAnnals Of Oncology, 2005
- The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapiesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2005
- Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trialsEmerging Drugs, 2003